Wealth Awesome
TSX open
Loading markets…
PARTNER SPOTLIGHT
CIBC Investor's Edge

Trade ETFs with $0 commission

Buy and sell over 200 ETFs to build your portfolio, commission-free.¹

  • ✓Over 200 eligible ETFs, commission-free when you trade online
  • ✓Screeners and tools to find ETFs that fit your goals
  • ✓Any account type, backed by the CIBC Digital Banking Guarantee

¹Online trades in ETFs on the Eligible ETF List; hold at least one business day. ETF fund fees still apply. Conditions apply.

Stocks

Spectral Med Inc EDT Earnings Beat Estimates by 300.0%

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:EDT.TO

Follow EDT

Photos provided by Pexels

Spectral Med reported positive quarterly EPS, beating expectations for a loss. Its FDA review and financing remain key parts of the investment story.

Spectral Med Inc. (TSX: EDT) reported earnings before the market opened on November 6, 2026, for the quarter ended September 30. EPS was C$0.02, compared with an estimate of -C$0.01. The company reported a 300.0% surprise. One analyst’s revenue estimate was C$604,000, but no actual revenue figure was provided, so it’s not possible to tell whether revenue beat or missed expectations. For Canadian investors, the result is one data point for a company still awaiting FDA review and relying on financing to support its operations.

Recent earnings trend

Spectral Med Inc

EDT.TO

Full stock page →

EDT.TO

Spectral Med Inc

Source:WealthAwesomeWealthAwesome
↓ $0.40 (-28.17%)
120 day period
$0.88$1.15$1.42May 27Aug 21Nov 16

Market cap

$293.55M

52W high

$1.52

52W low

$0.86

1W change

-5.56%

Beta

0.19

Analyst Price Targets

Based on analyst covering EDT · as of Sep 17, 2026

📈

Wall Street analysts forecast EDT stock price to rise 208.8% over the next 12 months.

Consensus

Bullish

Based on avg. target vs last close (formal rating unavailable for Canadian listings)

Avg. Target

C$3.15

+208.8% Upside

Current Price

C$1.02

Last close

Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on EDT's historical volatility

HistoricalForecast68%95%
C$0.33C$0.70C$1.07C$1.44C$1.81C$2.18TodayJul 9Sep 14Nov 16Dec 29Feb 11Mar 26

30-Day Vol

75.9%

Annualized

90-Day Vol

52.3%

Annualized

Trend (90d)

-50.0%

Annualized drift

90d Mean

C$0.85

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$0.96C$0.74 – C$1.25
60 trading daysC$0.91C$0.63 – C$1.31
90 trading daysC$0.85C$0.54 – C$1.34

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Analyst coverage: 1 analyst(s) cover this name; upcoming EPS consensus is available.

Beat estimates in 3 of the last 4 comparable quarter(s).

Fiscal periodReport dateActual EPSEstimateSurprise
2026-12-312027-03-29—-0.0100—
2026-09-302026-11-060.0200-0.0100+300.0%
2026-06-302026-08-070.0011-0.0100+111.0%
2026-03-312026-05-08-0.0100-0.0100+0.0%
2025-12-312026-03-26-0.0100-0.0200+50.0%
2025-09-302025-11-07-0.1100-0.0100-1000.0%
-0.1100-0.04500.0200 24-1225-0325-0625-0925-1226-0326-0626-09 Estimate Actual (≥0) Actual (<0) Wealth Awesome

Investor takeaway: EPS came in above expectations, and Spectral has beaten estimates in three of its last four reported quarters. Still, the figures are small: trailing-twelve-month (TTM) EPS is -C$0.03, and the reported profit margin is 0.00%. The company says recent financing should fund operations through the expected FDA PMA decision. The timing and outcome of the review remain uncertain. See the EDT stock page for company and share information.

C$0.02 EPS versus -C$0.01 estimated

EPS was 300.0% above the calendar estimate, but that estimate was a loss. The result doesn’t show that the company has reached lasting profitability. EPS was -C$0.11 in the same quarter last year, and TTM EPS remains -C$0.03.

Bull case

EPS improved to C$0.02 from -C$0.11 a year earlier, beating the -C$0.01 estimate. In a September update, Spectral said the FDA had requested clarification, further data analysis and testing, but no additional clinical trial. The company is preparing a response and says recent financing should cover operations through the expected PMA decision. Addressing the FDA’s feedback and moving the review forward would be an important milestone.

Bear case

One quarter of positive EPS doesn’t establish lasting profitability. TTM EPS is still negative, and the reported margin is 0.00%. The revenue estimate implied a 10.5% year-over-year decline, but actual revenue wasn’t included in the earnings data. The FDA review still requires a response, and its timing and outcome are uncertain.

Financing is another consideration. Spectral announced the second tranche of a C$14 million convertible-note private placement. The funds support operations, but the financing also carries potential dilution. The shares closed at C$1.02, below their 50-day average of C$1.11 and 200-day average of C$1.30.

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: November 17, 2026
Last Updated: November 17, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26